| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 11th April 2019 | Roger Hawley | 454,545 | Open or private purchase | $1.10 | $499,999.50 |
| 29th March 2019 | Roger Hawley | 15,700 | Open or private sale | $55.00 | $863,500.00 |
| 29th March 2019 | Roger Hawley | 5,000 | Open or private sale | $55.00 | $275,000.00 |
| 29th March 2019 | Roger Hawley | 5,000 | Exercise of derivative | $20.00 | $100,000.00 |
| 29th March 2019 | Roger Hawley | 15,700 | Exercise of derivative | $33.92 | $532,544.00 |
| 14th March 2019 | Roger Hawley | 38,789 | Open or private sale | $52.93 | $2,053,260.80 |
| 13th March 2019 | Roger Hawley | 21,211 | Open or private sale | $53.10 | $1,126,215.01 |
| 1st March 2019 | Roger Hawley | 3,125 | Exercise of derivative | $32.00 | $100,000.00 |
| 1st March 2019 | Roger Hawley | 1,175 | Exercise of derivative | $33.92 | $39,856.00 |
| 1st March 2019 | Roger Hawley | 4,300 | Open or private sale | $50.00 | $215,000.00 |
Cerulean Pharma
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Ticker: CERU
Sector: Unknown
Industry: Unknown
SEC Central Index Key (CIK): 1401914
Employees:
Exchange: None
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $5 M (11%)
Assets, Current: $8 M (20%)
Property, Plant and Equipment, Net: $55 Th (-13%)
Other Assets, Noncurrent: $739 Th (-21%)
Assets: $9 M (15%)
Accounts Payable, Current: $2 M (58%)
Accrued Liabilities, Current: $2 M (-21%)
Liabilities, Current: $6 M (8%)
Liabilities: $8 M (17%)
Common Stock, Value, Issued: $3 Th (44%)
Common Stock, Shares, Issued: $29 M (44%)
Additional Paid in Capital, Common Stock: $56 M (25%)
Retained Earnings (Accumulated Deficit): $55 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $113 Th (10%)
Stockholders' Equity (Parent): $311 Th (0%)
Liabilities and Equity: $9 M (15%)
Research and Development: $6 M (-30%)
General and Administrative Expenses: $2 M (-54%)
Operating Income/Loss: $7 M (-37%)